GE HealthCare to acquire Sofie Biosciences for $945 million
GEHC•GE HealthCare will acquire Sofie Biosciences for $945 million in cash, establishing a U.S. “final mile” footprint for PET radiopharmaceutical supply. The deal is expected to be accretive to adjusted EBIT margin and adjusted EPS in its first year.
1. Acquisition terms
GE HealthCare will buy Sofie Biosciences for $945 million in cash. The deal is expected to be accretive to adjusted EBIT margin and adjusted EPS in its first year.
2. Sofie to operate independently
Sofie Biosciences will continue to operate as an independent manufacturing partner to its customers.
